Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Lode Wigersma - Selling Sickness 2010


Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Lode Wigersma - Selling Sickness 2010

  1. 1. Selling Sickness Guidelines in the Netherlands<br />Dr Lode Wigersma, MD, PhD<br />Director of policy, KNMG (Royal Dutch Medical Association)<br />Vice Chair, CGR (Foundation for the Code of Pharmaceutical Advertising)<br />
  2. 2. Outline<br />Overview of Dutch regulatory system<br />Background Guidelines<br />Content of the Guidelines<br />Conclusion and questions<br />
  3. 3. Overview of the Dutch regulatory system<br />Dutch Medicines Act<br />Supervision IGZ (Inspectorate of Health Care)<br />Self regulation Codes:<br />Code of Pharmaceutical Advertising<br />Supervision CGR (Foundation for the Code of Pharmaceutical Advertising<br />Code of Public Promotion of Medicines<br />Supervision KOAG (Inspection Board for the Public Promotion of Medicines)<br />
  4. 4. <ul><li>Legislation
  5. 5. Penalties</li></ul>Working<br />Agreements<br /><ul><li> Focus on practitioners
  6. 6. Guidelines for:
  7. 7. Advertisement to health </li></ul>professionals<br /><ul><li> Hospitality and gifts
  8. 8. Non-interventionals studies
  9. 9. Sponsoring
  10. 10. Focus on general public
  11. 11. Guidelines for advertisement of:
  12. 12. OTC/Selfcare medicines
  13. 13. Food supplements
  14. 14. Medical (selfcare) devices
  15. 15. Guidelines for information of:
  16. 16. Prescription-only-medicines</li></li></ul><li>Self regulation in the Netherlands<br />CGR (Foundation for the Code of Pharmaceutical Advertising), since 1998<br />Advertising aimed at healthcare professionals<br />KOAG (Inspection Board for the Public Promotion of Medicines), since 1926<br />Advertising – if allowed - aimed at the public<br />
  17. 17. Partiesbehind the selfregulation<br />
  18. 18. Guidelines in the NetherlandsBackground <br />Increase disease awareness campaigns<br />Need/call for information on prescription-only-medicines from consumers/patients<br />Report “Gezonde Scepsis” (Healthy Skepticism)<br />Public and political attention in the Netherlands<br />Consulation meetings organised by CGR/KOAG<br />
  19. 19. Content of the guidelines<br />Standards for information on disease and prescription-only-medicines to general public<br />Basic principle: Information is not forbidden<br />Applicable to all parties concerned<br />
  20. 20. Scope of the guidelines<br />Information on diseases<br />General public<br />No reference (direct nor indirect) to POM <br />Information on diseases<br />Technical information<br />General public<br />Reference (direct or indirect to POM)<br />Information on diseases<br />Technical information <br />Individual questions <br />Users of medicines<br />Not public<br />
  21. 21. Most important conditions I <br />Balanced and complete<br />All relevant treatments <br />Same manner<br />Categorising <br />Not withhold or neglect information on purpose or without justifiable cause<br />
  22. 22. Most important conditions II<br />Applies to all linked media<br />Not misleading<br />No frightening pictures<br />Not lead to wrong self-diagnoses or unnecessary medical treatment<br />No guarantees of state that use of medicines is safe<br />
  23. 23. Most important conditions III<br />Self tests – validated and verified<br />Testimonials – true reproduction – no before and after situation<br />Children - prudently<br />Visual materials – difference health care professionals / public<br />
  24. 24. Corporate websites –<br />Not all relevant treatments<br />Only technical user information<br />Minor disease information – necessary for good understanding of treatment with specific prescription-only-medicine<br />
  25. 25. Transitional period<br />Effective October, 1st 2010<br />Transitional period six months April 1, 2011<br />Adjusting existing information<br />Evaluation of practical effects of Guidelines<br />
  26. 26. THANK YOU<br />